Heme Oxygenase-2 Deletion Causes Endothelial Cell Activation Marked by Oxidative Stress, Inflammation, and Angiogenesis

被引:51
作者
Bellner, Lars [1 ]
Martinelli, Lucia [1 ]
Halilovic, Adna [1 ]
Patil, Kiran [1 ]
Puri, Nitin [1 ]
Dunn, Michael W. [1 ]
Regan, Raymond F. [2 ]
Schwartzman, Michal Laniado [1 ]
机构
[1] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA
[2] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA
基金
美国国家卫生研究院;
关键词
NF-KAPPA-B; GROWTH-FACTOR RECEPTOR-1; ANTIOXIDANT; INHIBITION; MECHANISMS; EXPRESSION; INDUCTION;
D O I
10.1124/jpet.109.158352
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In previous studies, we have shown that heme oxygenase (HO)-2 null [HO-2(-/-/)] mice exhibit a faulty response to injury; chronic inflammation and massive neovascularization replaced resolution of inflammation and tissue repair. Endothelial cells play an active and essential role in the control of inflammation and the process of angiogenesis. We examined whether HO-2 deletion affects endothelial cell function. Under basal conditions, HO-2(-/-) aortic endothelial cells (mAEC) showed a 3-fold higher expression of vascular endothelial growth factor receptor 1 and a marked angiogenic response compared with wild-type (WT) cells. Compared with WT cells, HO-2(-/-) mAEC showed a 2-fold reduction in HO activity and marked increases in levels of gp91(phox)/NADPH oxidase isoform, superoxide, nuclear factor kappa B activation, and expression of inflammatory cytokines, including interleukin (IL)-1 alpha and IL-6. HO-2 deletion transforms endothelial cells from a "normal" to an "activated" phenotype characterized by increases in inflammatory, oxidative, and angiogenic factors. This switch may be the result of reduced HO activity and the associated reduction in the cytoprotective HO products, carbon monoxide and biliverdin/bilirubin, because addition of biliverdin to HO-2(-/-) cells attenuated angiogenesis and reduced superoxide production. This transformation underscores the importance of HO-2 in the regulation of endothelial cell homeostasis.
引用
收藏
页码:925 / 932
页数:8
相关论文
共 35 条
[1]   Pharmacological and clinical aspects of heme oxygenase [J].
Abraham, Nader G. ;
Kappas, Attallah .
PHARMACOLOGICAL REVIEWS, 2008, 60 (01) :79-127
[2]   Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase [J].
Ago, T ;
Kitazono, T ;
Ooboshi, H ;
Iyama, T ;
Han, YH ;
Takada, J ;
Wakisaka, M ;
Ibayashi, S ;
Utsumi, H ;
Iida, M .
CIRCULATION, 2004, 109 (02) :227-233
[3]   Exacerbated corneal inflammation and neovascularization in the HO-2 null mice is ameliorated by biliverdin [J].
Bellner, Lars ;
Vitto, Marco ;
Patil, Kiran A. ;
Dunn, Michael W. ;
Regan, Raymond ;
Laniado-Schwartzman, Michal .
EXPERIMENTAL EYE RESEARCH, 2008, 87 (03) :268-278
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]   Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltration [J].
Bussolati, B ;
Ahmed, A ;
Pemberton, H ;
Landis, RC ;
Di Carlo, F ;
Haskard, DO ;
Mason, JC .
BLOOD, 2004, 103 (03) :761-766
[6]   Discovering the neural basis of human social anxiety: A diagnostic and therapeutic imperative [J].
Charney, DS .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (01) :1-2
[7]   Induction of cytoprotective genes through Nrf2/antioxidant response element pathway: A new therapeutic approach for the treatment of inflammatory diseases [J].
Chen, XL ;
Kunsch, C .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (08) :879-891
[8]  
Frey RS, 2009, ANTIOXID REDOX SIGN, V11, P791, DOI [10.1089/ars.2008.2220, 10.1089/ARS.2008.2220]
[9]   Biliverdin inhibits activation of NF-κB:: Reversal of inhibition by human biliverdin reductase [J].
Gibbs, Peter E. M. ;
Maines, Mahin D. .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (11) :2567-2574
[10]   20-hydroxyeicosatetraenoic acid stimulates nuclear factor-κB activation and the production of inflammatory cytokines in human endothelial cells [J].
Ishizuka, Tsuneo ;
Cheng, Jennifer ;
Singh, Harpreet ;
Vitto, Marco D. ;
Manthati, Vijay L. ;
Falck, John R. ;
Laniado-Schwartzman, Michal .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 324 (01) :103-110